Fed. Circ. Revives Leo Psoriasis Drug Patent

Law360, New York (August 12, 2013, 8:21 PM EDT) -- The Federal Circuit on Monday reversed a U.S. Patent and Trademark Office decision invalidating a Leo Pharmaceutical Products Ltd. patent for a psoriasis treatment, ruling the office ignored "compelling" evidence that the patent should not have been found obvious.

When it reexamined the patent at the request of Leo's rival Galderma SA, the USPTO's Patent Trial and Appeal Board concluded that it would have been obvious in view of three older patents. However, the Federal Circuit said that those patents did not address the problems with storing the drug that Leo solved with its invention.

Leo's patent solving the problem was...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!